BOCA RATON, Fla., May 8, 2019 /PRNewswire/ -- Sensus Healthcare,
Inc. (NASDAQ: SRTS), a medical device company specializing in novel
radiation oncology technologies and solutions, has been awarded a
group purchasing agreement for Brachytherapy Products with Premier.
Effective August 1, 2019, the new
agreement allows Premier members, at their discretion, to take
advantage of special pricing and terms pre-negotiated by Premier
for Sensus' SRT-100™ Superficial Radiation Therapy systems.
"Premier is a well-established and respected organization," said
Joe Sardano, CEO, Sensus Healthcare.
"We are proud of our relationship with the company and its 4,000+
member hospitals and health systems and over 165,000 other
providers."
SRT delivers precise, calibrated, low-dose radiation that
effectively destroys basal and squamous cell carcinomas, as well as
the non-malignant tumor cells that cause keloids. Each treatment is
virtually painless and doesn't involve cutting, bleeding, stitching
or anesthesia. There is also no risk of infection or scarring and
no need for reconstructive plastic surgery. Sensus'
SRT-100™ is cleared by the U.S. Food and Drug
Administration (FDA) for the treatment of both non-melanoma skin
cancers and keloids.
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,000 U.S. hospitals and 165,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions and advisory and
other services, Premier enables better care and outcomes at a lower
cost.
About Sensus Healthcare
Sensus Healthcare, Inc., is a
medical device company specializing in highly effective,
non-invasive, minimally invasive and cost-effective treatments for
both oncological and non-oncological conditions. The Sculptura™
robotic radiation oncology system provides targeted intraoperative
triple-modulated radiotherapy (IORT) and brachytherapy utilizing
our proprietary, state-of-the-art 3D Beam Sculpting™ to treat
patients undergoing cancer treatment during surgery, or at the
tumor site, with a single dose. Sensus also offers its proprietary
low-energy X-ray technology known as superficial radiation therapy
(SRT), which is the culmination of more than a decade of research
and development, to treat non-melanoma skin cancers and keloids
with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its
portfolio of innovative medical device products, Sensus provides
revolutionary treatment options to enhance the quality of life of
patients around the world.
For more information, visit
https://www.sensushealthcare.com.
Forward-Looking Statements
This press release
includes statements that are, or may be deemed, ''forward-looking
statements.'' In some cases, these forward-looking statements can
be identified by the use of forward-looking terminology, including
the terms "believes," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should,"
"approximately," "potential" or, in each case, their negative or
other variations thereon or comparable terminology, although not
all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics,
and healthcare, regulatory and scientific developments and depend
on the economic circumstances that may or may not occur in the
future or may occur on longer or shorter timelines than
anticipated. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this press release,
we caution you that forward-looking statements are not guarantees
of future performance and that our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of,
among other factors: our ability to achieve and sustain
profitability; market acceptance of our product lines; our ability
to successfully commercialize our products; our ability to compete
effectively in selling our products and services, including
responding to technological change and cost containment efforts of
our customers; our need and ability to obtain additional financing
in the future, as well as complying with the restrictions our
existing revolving credit facility imposes; our ability to expand,
manage and maintain our direct sales and marketing organizations;
our actual financial results may vary significantly from forecasts
and from period to period; our ability to successfully develop new
products, improve or enhance existing products or acquire
complementary products, technologies, services or businesses; our
ability to obtain and maintain intellectual property of sufficient
scope to adequately protect our products, and our ability to avoid
infringing or otherwise violating the intellectual property rights
of third parties; market risks regarding consolidation in the
healthcare industry; the willingness of healthcare providers to
purchase our products if coverage, reimbursement and pricing from
third party payors for procedures using our products declines; the
level and availability of government and third party payor
reimbursement for clinical procedures using our products; our
ability to effectively manage our anticipated growth, including
hiring and retaining qualified personnel; the regulatory
requirements applicable to us and our competitors; our ability to
manufacture our products to meet demand; our reliance on third
party manufacturers and sole- or single-source suppliers; our
ability to reduce the per unit manufacturing costs; our ability to
efficiently manage our manufacturing processes; the regulatory and
legal risks, and certain operating risks, that our international
operations subject us to; off label use of our products; the fact
that product quality issues or product defects may harm our
business; the accuracy of our financial statements and accounting
estimates, including allowances for accounts receivable and
inventory obsolescence; any product liability claims; limited
trading in our shares and the concentration of ownership of our
shares; cyberattacks and other data breaches and the adverse effect
on our reputation; new legislation, administrative rules, or
executive orders, including those that impact taxes and
international trade regulation; the provisions in our certificate
of incorporation, bylaws, or Delaware law that discourage takeovers or that
limit certain disputes to be brought exclusively in the
Delaware Court of Chancery;
concentration of our customers in the U.S. and China, including the concentration of sales to
one particular customer in the U.S.; and other risks described from
time to time in Sensus Healthcare's filings with the Securities and
Exchange Commission, including the Company's Annual Report on Form
10-K.
In addition, even if our results of operations, financial
condition and liquidity, and the development of the industry in
which we operate are consistent with the forward-looking statements
contained in this press release, they may not be predictive of
results or developments in future periods. Any forward-looking
statements that we make in this press release speak only as of the
date of such statement, and we undertake no obligation to update
such statements to reflect events or circumstances after the date
of this press release. You should read carefully our "Cautionary
Note Regarding Forward-Looking Information" and the factors
described in the "Risk Factors" section of our periodic reports
filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
MEDIA CONTACT:
Caitlin Kasunich / McKenna Miller
212-896-1241 / 347-487-6197
ckasunich@kcsa.com / mmiller@kcsa.com
INVESTOR CONTACT:
Kim Sutton
Golodetz
212-838-3777
kgolodetz@lhai.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sensus-healthcare-awarded-brachytherapy-products-agreement-with-premier-300845748.html
SOURCE Sensus Healthcare